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This report includes our study of some optimization problems that arise when modeling the usual
chemotherapy treatments for cancer. Gompertz-type tumor growth is considered and that the effect
of the drug is proportional to the growth rate of the untreated tumor (Norton-Simon hypothesis).
Also, we use classical pharmacokinetics and two pharmacodynamics: Skipper and Emax.
We study optimization problems for initially fixed dosage times, and we find explicit expressions
for their solutions. We show examples that contrast this theoretical study. As far as we know,
these are results that have not been published previously.
In addition, we present several numerical results made with MATLAB for two types of drugs
used in chemotherapy: one with a long half-life (Cabazitaxel) and another with a short half-life
(Temozolomide).
Key words: Optimization problems, chemotherapy, Norton-Simon hypothesis, Skipper model,
Emax model.
Resumen
Esta memoria recoge un estudio propio de algunos problemas de optimización que surgen al
modelizar los tratamientos habituales de quimioterapia para el cáncer. Se considera el crecimiento
tumoral de tipo Gompertz y que el efecto del fármaco es proporcional a la tasa de crecimiento del
tumor no tratado (hipótesis de Norton-Simon). Además, utilizamos la farmacocinética clásica y
dos farmacodinámicas: Skipper y Emax.
Estudiamos los problemas de optimización con tiempos de dosificación fijos inicialmente, y hallamos
expresiones expĺıcitas para sus soluciones. Mostramos ejemplos que contrastan el estudio teórico.
Hasta donde nosotros sabemos, son resultados que no han sido publicados previamente.
Además, presentamos varios resultados numéricos realizados con MATLAB para dos tipos de
fármacos usados en quimioterapia: uno de vida media larga (Cabazitaxel) y otro de vida media
corta (Temozolomide).
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1.1 Chemotherapy: history, purpose and use
Cancer is a process of uncontrolled cell growth and spread. There are many types of treatment
for this disease, depending on the type and stage of the cancer (how advanced it is, the size of the
tumor...). The most common treatments today are surgery, immunotherapy, radiation therapy,
and chemotherapy. Chemotherapy is a type of cancer treatment that uses drugs to kill cancer
cells. Chemotherapy treatments began to be developed in the early 20th century, and it began to
be used to treat cancer in the 1940s.
Depending on the type of tumor and its condition, chemotherapy can have two principal purposes:
• Curative: Its aim is to cure the disease, when it is in a suitable phase. Chemotherapy can
reduce the size of a tumor before surgery or radiation therapy. Also, another of its purposes
may be to help other treatments work better.
• Palliative: If the state of the tumor is very advanced, chemotherapy can be used in order to
control the symptoms produced by it, reduce pain, and in some cases, increase the patient’s
survival.
There are different ways of administering chemotherapy: intravenous (the most common), oral
(for drugs that can be absorbed through the stomach or intestine), or directly in an hospital if
important safety measures are needed.
1.2 Metronomic chemotherapy and MTD therapy
The most common therapies in cancer treatments with chemotherapy are MTD therapy and
metronomic chemotherapy:
• MTD (Maximum Tolerated Dose) therapy consists on administering the maximum
tolerated dose with longer rest periods. Its goal is to be as harmful as possible with cancer
cells. However, the damage that this type of therapy can cause to healthy cells near the
tumor tissue must be taken into account (see [10]).
• Metronomic chemotherapy consists of the administration of low doses of the drug over
long periods of time and with the minimum possible spacing between doses. By administering
the drug in low doses, it is hoped to reduce the toxic effects of the treatment. In addition,
being long lasting treatments it is expected to improve the overall effect of the treatment
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(see for instance [16]). This therapy is relatively recent (in 2007 there was a talk of it as a
new therapeutic strategy for the treatment of breast cancer, see [6]).
1.3 Mathematics in chemotherapy
There are numerous studies that highlight the importance of mathematical models (based on
differential equations) in the development of better schedules for chemotherapy treatments (through
optimization problems), as well as to predict the effect of certain drugs on patients (see for instance
[3] and [12]).
In the mid-1970s, the optimal control theory for chemotherapy treatments was first applied,
assuming the log-kill hypothesis, which will be explained in Chapter 2. Therefore, many articles
highlight the usefulness of mathematical models to find more effective and less toxic treatments
(see [8]).
We can consider different ODE models, such as: exponential, logistic, Bertalanffy for the untreated
tumor, which are studied in [1]. In this study we will consider the problems that arise when
modeling usual chemotherapy treatments under the assumptions of Gompertz-type tumor growth
and the Norton-Simon hypothesis (the effect of the drug is proportional to the growth rate of the
untreated tumor). That seem to provide a more precise and realistic framework for chemotherapy
(see [8]). In addition we will consider the classical pharmacokinetics and two pharmacodynamics:
Skipper and Emax (see Chapter 2).
1.4 Contribution and structure of the work
The interest of this work lies in the fact that it is an innovative study that has not been reported
previously, as far as we know. As we have already mentioned, we have based the line of research
on the Norton-Simon hypothesis. Most of the mathematical works we have found in this area are
restricted to a simpler framework (such as the log-kill hypothesis). However, we have not found
any in-depth mathematical studies using Norton-Simon’s hypothesis, nor any that reach the results
which we have achieved.
The complexity of this work is also illustrated by the fact that the optimization problems studied
are mixed, nonlinear, and with numerous variables. In most cases we have obtained explicit
expressions of the solutions based on the initial data. For the practical cases, we have carried
out numerous programs in MATLAB that have allowed us to make simulations to contrast the
theoretical results and, in some cases, to study problems which are complex in their theoretical
analysis. We have selected two drugs for the numerical simulations, which we have chosen after
analyzing different possibilities, because they were those that gave us more variety in the results as
they had very different characteristics. At the same time, both drugs are very used in the clinical
practice.
With this work we want to contribute to the study of the theory of optimization in chemotherapy
bringing unpublished results and leaving open lines to continue the research.
This report is divided into five chapters. After this introduction, in Chapter 2 we will present the
pharmacokinetics and pharmacodynamics models used, and the optimization problems which will
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be studied in the following. In Chapters 3 and 4 we will study the above optimization problems
for Skipper and Emax models, respectively, their solution and other characteristics, also providing
examples to illustrate the theoretical results. Also, in those chapters we will make some numerical
simulations for two different drugs, which have different half-life: Temozolomide and Cabazitaxel.
Finally, Chapter 5 reviews the results obtained in the previous chapters following the investigations




The objective of this chapter is to give the general formulation of the optimization problems
that we are going to study. For this purpose, we will first deal with some aspects related to
pharmacology1: pharmacodynamics (PD) and pharmacokinetics (PK). Pharmacodynamics is the
study of the biochemical and physiological effects of drugs and their mechanisms of action on the
organism. On the other hand, pharmacokinetics studies the processes a drug undergoes from the
time it is administered until it is eliminated by the body. As an intuitive idea, we can say that
pharmacodynamics can be defined as “what a drug does to the body” and pharmacokinetics as
“what the body does to a drug”.
As for the drugs used in chemotherapy, we are going to introduce two concepts: the volume of
distribution of a drug (VD) is the theoretical volume (studied in pharmacology) that would be
necessary to ensure that all organs or compartments have the same concentration of the drug as
in the blood plasma (see [24]). Depending on the type of drug, its units can be L or L/kg if it
depends on the patient’s weight. Also, many of these drugs are administered according to the
patient’s body surface area (BSA) which (on average) for men is 1.9 m2 and for women is 1.6 m2
(see, for instance [20]).
2.1 Pharmacokinetics
Let c(t) be the concentration of the drug in the body at the instant of time t. The simplest
pharmacokinetics model that we can consider is that the body does not interact with the drug,
but it is unrealistic although in some works this simplification is used. Instead, let’s consider the
following first-order Cauchy problem:{
c′(t) = −λc(t) + u(t)
c(0) = 0
.
The term −λc(t) represents that the body is eliminating the drug, and the function u(t) depends
on the drug and the way it is administered. In our work, taking into account that N doses {di}Ni=1









1Pharmacology is the study of drugs and their action.
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where δ(t− ti) is the Dirac delta distribution concentrated at ti.
Therefore, the term u(t) represents that a di dose of the drug is given at the instant ti. Then, the
Cauchy problem takes the following form: c






To solve problem (2.1), we must do it separately in each interval and we get the following results:




and therefore we get that c(t) = 0.
• In [t1, t2):
{
c′(t) = −λc(t)
c(t+1 ) = σd1
and we get that c(t) = σd1e
λ(t1−t).
• In [t2, t3):
{
c′(t) = −λc(t)
c(t+2 ) = σ(d1e
λ(t1−t2) + d2)
and then c(t) = σe−λt(d1e
λt1 + d2e
λt2).
• Proceeding inductively, we obtain the following values for c(t):
c(t) =

0 t ∈ [0, t1)
σe−λtd1e
λt1 t ∈ [t1, t2)
σe−λt(d1e
λt1 + d2e





λt2 + · · ·+ dN−1eλtN−1) t ∈ [tN−1, tN )
σe−λt(d1e
λt1 + d2e
λt2 + · · ·+ dNeλtN ) t > tN
. (2.2)
2.2 Pharmacodynamics
In the following equations, L(t) represents the volume of the tumor at time t, ξ is its growth rate
and, θ the maximum size it can reach. In practice θ can change over time, but we will focus on
the problem in which θ is fixed. Also, we are going to consider θ = 1 as the maximum size of the
tumor, therefore, if the volume of the tumor is 0.2, we are meaning that it is 20% of the maximum
size.
Although several mathematical models can be considered for the study of tumor growth, such as
the logistic or exponential, in this case we will use the Gompertzian one, which has been considered
recently in numerous studies (see [1]). It is given by the ODE:






There are different models to formulate the effect of chemotherapy on the volume of the tumor,
the most basic one is known as log-kill hypothesis:






The log-kill hypothesis establishes that a given dose of drug on a chemotherapy treatment kills
the same fraction of tumor cells regardless of the size of the tumor at the time of treatment [13].
Note that ρ̃(t) is related to the level of therapy and the two classic expressions are:
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• Skipper: ρ̃(t) = k1c(t), with k1 ∈ R, k1 > 0.
• Emax: ρ̃(t) = k1c(t)
k2 + c(t)
, with k1, k2 ∈ R, k1, k2 > 0.
In both cases, k1 and k2 are constants that are experimentally estimated. In this study we are
going to consider the Norton-Simon hypothesis [8]. It states that the rate of cancer cell death due
to the treatment is directly proportional to the tumor growth rate at the time of treatment. That















) = ξ (1− ρ̃(t)).
We integrate to reach the solution:


























Note that the volume of the tumor L(t) depends on the value of
∫ t
0
(1− ρ̃(s))ds. We are interested
in calculating L(T ) (the tumor size at T , the final time to study, fixed a priori, with T ≥ tN ). As
the value of ρ̃(s) depends on the model considered (Skipper or Emax), L(T ) varies according to
the model under study:

















2.3 Associated optimization problems
We are going to study two different optimization problems that arise when modeling the usual
chemotherapy treatments for cancer, under the assumptions of tumor growth of the Gompertz
model and the Norton-Simon hypothesis, considering the classical pharmacokinetic and the Skipper
or Emax pharmacodynamic in each case. Be the times in which the doses are given 0 ≤ t1 < . . . <
tN ≤ T , fixed during all this work. In addition, each given dose must be between a maximum
dose, dmax, (for reasons of toxicity), and above a minimum dose, dmin > 0, so that the treatment
is effective.
• In the first problem, the goal is to minimize the volume of the tumor, subject to a total dose,
D > 0, which is divided into N doses, {di}Ni=1 in the treatment period. Hence we consider









dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N},
, (2.8)
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dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N},
, (2.9)
• Now, let’s present the problem in which we want to maintain the tumor volume under a
level that is not harmful to the patient, allowing him to lead a normal life (formulations
considered, for example, in [4] and [9]). Then, be L∗ the maximum tumor size allowed at
the final time T . We are going to minimize the total dose that a patient should take for
a specified period of time so that the volume of the tumor at T does not exceed L∗. We







N ∈ N, d ∈ RN
subject to L(T ) ≤ L∗
dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N},
, (2.10)
with L∗ ∈ (0, 1).
Let’s see a condition equivalent to L(T ) ≤ L∗:



















































































ρ̃(s)ds ≥ T + γ̃
dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}.
. (2.12)
In Chapters 3 and 4 we are going to consider these two problems, (P̂1) and (P̂2) for the two







In this chapter we consider (2.5) with the Skipper model for the level of therapy, in which
ρ̃(t) = k1c(t), with k1 > 0 a given constant and c(t) as we have defined in (2.2).
We are interested in the formulation that takes in this case the two optimization problems raised















λt2)ds+ · · ·+∫ tN
tN−1
σe−λs(d1e



















































































Then, we get the following expression for L(T ):




















3.1 Minimizing the tumor volume with a fixed cumulative dose
We will start by considering the problem (P̂1) defined in Section 2.3, in which we want to minimize
the tumor volume at time T . Using (3.1), σ, λ > 0, we reformulate the problem (P̂1) as follows:
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(P1S)













dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N},
.
Note that (P1S) is a mixed optimization problem, that is, it has N continuous variables, d, and
an integer variable, N . In order to have a non-empty set of feasible points, N must take a finite
number of values (N ∈ [ Ddmax ,
D
dmin
] ∩ N). We are interested in solving this problem for each of
these values. Furthermore, by setting the value of N , we are going to solve the following problem:
(PN1S)










dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}
.
with 0 < wN < . . . < w2 < w1 < 1. In the two following theorems we consider a general array w, so
they are valid for a more general problem where the coefficients of the objective function verify the
previous inequality. Later, when we come back to (P1S) resolution, we will take wi = 1− eλ(ti−T )
(remember that {ti}Ni=1 are fixed and verify 0 ≤ t1 < t2 < . . . < tN ≤ T ).








∩ N, then the problem (PN1S) has, at least, a
solution.
Proof. Be K1 the set of restrictions of the problem (P
N








∩N, then K1 6= ∅.
Let’s consider the following continuous functions:




• ĝi : RN −→ R such as ĝi(d) = di, ∀i ∈ {1, . . . , N}.











K1 is closed because it is an intersection of closed sets. Furthermore, as all the variables are
bounded, K1 is compact. Since K1 is compact and the function f
N
1 is continuous, there is at least
a global solution to the problem (PN1S) (see Appendix A).
Theorem 3.1.2. Under the hypothesis of the previous theorem, the solution of problem (PN1S) is:
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3. (dmax, . . . , dmax, d
∗, dmin, . . . , dmin) if
D
dmax
< N < Ddmin , N ∈ N,
with d∗ verifying dmin ≤ d∗ ≤ dmax and d∗ = D − (j0 − 1)dmax − (N − j0)dmin, where
j0 = max {j ∈ {1, . . . , N} : (j0 − 1)dmax + (N − j0 + 1)dmin ≤ D}.
Proof. Let’s study the different possible cases:
1. If D = Ndmin with N ∈ N, then d = (dmin, . . . , dmin) it is the solution of the problem
because is the unique feasible point.
2. If D = Ndmax with N ∈ N, then d = (dmax, . . . , dmax) is the unique feasible point.
3. If D ∈ (Ndmin, Ndmax) with N ∈ N:
• If D ∈ [(N − 1)dmax + dmin, Ndmax), d = (dmax, . . . , dmax, d∗) is the solution with
d∗ = D − (N − 1)dmax. Indeed, using w1 > w2 > . . . > wN , f(d) > f(d), ∀d ∈ RN , d
being a feasible point.
• If D ∈ [(N − 2)dmax + 2dmin, (N − 1)dmax + dmin), d = (dmax, . . . , dmax, d∗, dmin) is
the solution with d∗ = D − (N − 2)dmax − dmin. Again, using w1 > w2 > . . . > wN ,
f(d) > f(d), ∀d ∈ RN , d being a feasible point.
• IfD ∈ [(j0 − 1)dmax + (N − j0 + 1)dmin, j0 dmax + (N − j0)dmin), following the pattern
of the two previous cases, d = (dmax, . . . , dmax︸ ︷︷ ︸
j0−1
, d∗, dmin, . . . , dmin︸ ︷︷ ︸
N−j0
) is the solution of
(PN1S), with d
∗ = D − (j0 − 1)dmax − (N − j0)dmin, dmin ≤ d∗ ≤ dmax and with
j0 = max {j ∈ {1, . . . , N} : (j0 − 1)dmax + (N − j0 + 1)dmin ≤ D}.
In Theorem 3.1.2 we have seen that the solution of (PN1S) does not depend on the values of wi
against what might seem intuitively (although the value of the objective function depends on
them). Note that only the strictly decreasing order of these values has been used.
Now, we know how to solve (PN1S) for each value of N ∈ N,
D
dmax
≤ N ≤ Ddmin . Then, to try to
solve (P1S) we propose the following strategy:
• First, we can considerN = d Ddmax e, where dxe denotes the smallest integer that is not less than
x. Then, we solve the problem (PN1S) to get d
(N)
. To evaluate the objective function fN1 (d̄
(N))
we need to know the coefficients {wi}Ni=1 from the pre-set values of {ti}Ni=1 (according to the
specialists’ criteria).




Then, a solution of (P1S) is each tuple (N, d
(N)








To illustrate this procedure, let’s see an example (only for mathematical purposes) where we
consider the times fixed and solve (PN1S) for each feasible value of N .
Example 3.1.1. Be D = 1050 mg/m2, dmin = 100 mg/m
2, dmax = 200 mg/m
2, T = 28, λ = 0.1
and the times fixed for each value of N : t1 = 0 and ti+1 = 2 + ti ∀i ∈ {1, . . . , N − 1}. The values
have been chosen for illustrative purposes and they are not based on clinical practice. In order to
solve problem (P1S) with these data, we have to solve (P
N
1S) for N ∈ [5.25, 10.50] ∩ N:
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• If N = 8, then d(8) = (200, 200, 150, 100, . . . , 100︸ ︷︷ ︸
5
) and f81 (d
(8)
) = 923.38.
• If N = 9, then d(9) = (200, 150, 100, . . . , 100︸ ︷︷ ︸
7
) and f91 (d
(9)
) = 901.51.
• If N = 10, then d(10) = (150, 100, 100, . . . , 100︸ ︷︷ ︸
9
) and f101 (d
(10)
) = 871.48.
Finally, the solution for (P1S) in this case is the tuple (6, d
(6)
) because we get that max{fN1 (d
(N)
), N ∈
{6, . . . , 10}} = f61 (d
(6)
).
Once the general scheme for the resolution of the problem (P1S) is clear, note that the coefficients
of the objective function depend on λ, so we can distinguish two cases depending on the type of
drug used:




≈ 1, and as a consequence the influence of dosing times is
hardly noticeable and only total dose
N∑
i=1
di = D matters. For example, this would be the
case of short-lived drugs, whose treatments are carried out for long periods of time. Let’s go
back to the Example 3.1.1, and now consider the case of Temozolomide, where λ = 9.242:
Example 3.1.2. With the data of the Example 3.1.1 and λ = 9.242, we obtain five solutions
for (P1S): d̄
(N) for N ∈ {6, 7, 8, 9, 10}. In all these cases the numerical result fN1 (d̄(N)) =
1050 is obtained.
Also, in Table 3.1 in Section 3.3 we see that treatments 2 and 3 described in Figure 3.1
achieve the same objective (in both the same total dose is given). From the computational
point of view there are an infinite number of solutions in this case.











differently, so the dosing time influence the value of the objective function in the solution.
In Table 3.4 in Section 3.4 we will see an example of this situation for the drug Cabazitaxel,
with the treatments of 20 mg/m2 dose every 3 week and 10 mg/m2 dose once a week (in
both the same cumulative dose is given but the final tumor size is different).
To conclude this section, let’s look at an example of the influence of times on results, considering
the same doses:
Example 3.1.3. Be N = 6, d̄ = (200, 200, 200, 200, 200, 200), and t̃ = (1, 2, 3, 4, 5, 28), t̂ =
(1, 6, 11, 16, 21, 26), T = 29:
• If λ = 9.242, with both t̃ and t̂, fN1 (d̄) = 1200. In this case, we can see that there is no
influence of the time on the value of the objective function in d̄.
• If λ = 0.1, with t̃, fN1 (d̄) = 944.01 and with t̂, fN1 (d̄) = 842.19. We observe that in this case,
the dosing times influence the value of the objective function in d̄, giving a better result than
the one obtained with t̃.
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3.2 Minimizing the cumulative dose and keeping the tumor size
below a level
As in (2.10), we are interested in minimizing the given drug dose, but with a constraint on the
tumor size at the final time: L(T ) ≤ L∗, where L∗ is a given level beforehand. Using (2.11), the







≥ γ, with γ = λ
k1σ
(T + γ̃) . (3.3)
Remember that as we defined γ̃ in Section 2.3, this constant depends on the data ξ, θ, L0 and L∗.
Therefore the optimization problems (P2) and (P̂2) can be reformulated as follows:
(P2S)














dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}.
.
with dmin > 0 and γ ∈ R defined as in (3.3). This problem is a mixed optimization problem,
because it has continuous variables, d, and an integer variable, N . In this case, let us note that
there is an infinite set of feasible N values, but only a finite subset of them has practical interest.







. On the other hand,







≥ γ. Once we find that value,
it doesn’t make sense to take a higher value, since if N > N̂ , then f̃(N̂ , d̂) = N̂dmin < f̃(N, d)
for d̂ = (dmin, . . . , dmin) and for all (N, d) feasible for (P2S). If we fix the value of N we get the
following problem of N variables:
(PN2S)










dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}
.
with wi = 1 − eλ(ti−T ), 0 < wi < 1, ∀i ∈ {1, . . . , N} and w1 > w2 > . . . > wN . Note that this
problem can be interpreted similarly to the knapsack problem 1.
Theorem 3.2.1. If γ ≤
N∑
i=1
widmax, then there is, at least, a solution for (P
N
2S).
Proof. Be K2 the set of restrictions of the problem (P
N
2S). If γ ≤
N∑
i=1
widmax, then K2 6= ∅. From
K2 = g
−1







with g2(d) = −wTd+ γ and ĝi the same as that of
1It models a situation analogous to minimize the weight of the backpack contents with the restriction that the
contents provide a minimum level of nutrition. [22]
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problem (PN1S), we deduce that K2 is a closed and bounded set. As in addition f
N
2 is a continuous
function, we conclude that there is a global solution to the problem (PN2S) (see Appendix A).
Theorem 3.2.2. Under the hypotheses of the above theorem, the solution of the problem (PN2S) is
given by:








3. (dmax, . . . , dmax, d
∗, dmin, . . . , dmin) in other case, where

















Proof. Let’s study the three cases:
1. If γ =
N∑
i=1
widmax, then (dmax, . . . , dmax) is the solution of (P
N
2S), because it’s the unique
feasible point.
2. If γ ≤
N∑
i=1
widmin, then (dmin, . . . , dmin) is the solution of (P
N
2S) due to the components are
the lower bound for di, ∀i ∈ {1, . . . , N}.









. First let us note that (PN2S) is a linear
programming problem and the necessary and sufficient optimally conditions for d̄ being a

















2. µi(di − dmax) = 0, µi ≥ 0, ∀i ∈ {1, . . . , N}.
µ̂i(−di + dmin) = 0, µ̂i ≥ 0, ∀i ∈ {1, . . . , N}.
µ(−wTd+ γ) = 0, µ ≥ 0.
3. d̄ must also be feasible.
Moreover, let us show that those conditions imply that the general linear constraint is active
at d̄. If wTd > γ, using conditions 2 and 1 above, we get µ = 0, 1 + µi − µ̂i = 0, ∀i ∈





Now, we can distinguish several subcases:
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/w1 ∈ (dmin, dmax] verifies the optimality conditions above with
µ1, µ̂1 = 0, µi = 0, µ̂i = 1 − wiw1 , ∀i ∈ {2, . . . , N} and µ =
1
w1
. Let us note that,
using wi < w1, ∀i ∈ {2, . . . , N}, we get µ̂i ≥ 0.










, taking d̄1 = dmax and
arguing as in the previous subcase, we get that d̄ = (dmax, d
∗, dmin, . . . , dmin) is solution
of the problem (PN2S) with d
∗ verifying d∗ =
(





/w2 ∈ (dmin, dmax].
It is enough to take in Kuhn-Tucker conditions the values: µ̄1 = −1 + w1w2 , µ̂1 = 0,

















, we obtain that the
solution d is given by:
di =

dmax if i < j0
d∗ if i = j0
dmin if i > j0
,







 /wj0 , and
j0 = min








Finally let’s prove the uniqueness of solution: using the inequalities of the {wi}Ni=1 and that the
general inequality constraint is active in d̄, fN2 (d̄) < f
N
2 (d) for any other feasible point d.
From Theorem 3.2.2 we know the structure of the solution of problem (PN2S), so we have carried
out a program in MATLAB that solves it following the scheme of the theorem’s proof. Let’s see
an example in which we set the values of N , w, dmin, dmax and vary γ:
Example 3.2.1. Be N = 10, wi =
1
(i+ 1)2
, dmin = 10 mg/m
2 and dmax = 20 mg/m
2.
• If γ = 5, then γ < dmin
N∑
i=1
wi, so we obtain d = (10, . . . , 10︸ ︷︷ ︸
N
).
• If γ = 10, then we get as a solution d = (20, 20, 20︸ ︷︷ ︸
3
, 14.59, 10, . . . , 10︸ ︷︷ ︸
6
), with the value d∗ =
14.59 mg/m2 in the fourth position.
• If γ = 11, we get as a solution d = (20, . . . , 20︸ ︷︷ ︸
8
, 12.20, 10), with d∗ = 12.20 mg/m2 in the
ninth position.
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In the previous example we can see the usefulness of the theorem 3.2.2. As we know the structure
of the solution of the problem (PN2S), we can quickly calculate it. Also, in order to solve (P2S)
we have to do it for the different values of N with interest in the clinical practice which are also
conditioned by the desired duration of the treatment.
3.3 Temozolomide
Temozolomide (Temodar and Temodal) is an oral chemotherapy drug, used for the treatment of
refractory anaplastic astrocytoma, which is a type of cancerous brain tumor. Its half life2 is about
1.8 hours, and its volume of distribution (VD) is 0.4 L/kg (this information is available at [17]).
In Figure 3.1 we show the structure of the usual treatments which we will describe below:
Figure 3.1: Usual treatments with Temozolomide.
• Treatment 1: 28 days of treatment, in which the first 5 days a dose of 200 mg/m2 is given,
and the other 23 days no dose is given.
• Treatment 2: 28 days of treatment, in which the first 7 days doses of 150 mg/m2 are given,
the next 7 days (between the 8 and the 14) no dose is given, the next 7 days (between 15
and 21) 150 mg/m2 day dose, and the last 7 days no dose is administrated.
• Treatment 3: 28 days of treatment, in which the first 21 days doses of 100 mg/m2 are
administrated, and the other 7 days no dose is given.
• Treatment 4: 28 days of treatment, in which the first 21 days doses of 75 mg/m2 are given,
and the other 7 days no dose is administrated.
• Treatment 5: 28 days of treatment in which daily doses of 50 mg/m2 are given.
2The half-life of a drug is the time it takes to reduce to half the amount of agent present in the body, through
various elimination processes. This is a fundamental parameter for knowing the intervals of application of this drug
(see, for instance, [19]).
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First of all, we are going to estimate the value of λ of (2.1) using that the half-life of the
Temozolomide is about 1.8 hours (t̃ = 0.075 days):




−λt̃ =⇒ λ = log(2)
t̃
≈ 9.2419 days−1.
Let’s see how can we estimate the value of the parameter ξ of (2.3):





(see (2.7) with ρ̃ = 0). If we take θ = 1 as the
maximum tumor volume and L(t∗) = 2L(0), we get:
L(t∗) = 2L(0) = (L(0))exp(−ξt
∗) =⇒ log(2L(0)) = exp(−ξt∗) log(L(0)) =⇒
=⇒ exp(−ξt∗) = log(2L(0))
log(L(0))








The value of t∗ depends on the type of tumor and it is calculated experimentally. Taking L(0) =
0.03, we can make different estimations depending on the value of t∗, for example, for t∗ = 40
days, ξ ≈ 0.00551, for t∗ = 10 days, ξ ≈ 0.022, and for t∗ = 2 days, ξ ≈ 0.11. In this work we are
going to consider ξ = 0.00551 (also, see [7]).
Note that the given doses depend on whether the patient is male or female. In each treatment, we
estimate the mg of drug that must be given for m2, and we consider the average BSA which for
men is 1.9 m2 and for women is 1.6 m2 (see, for instance [20]). For the analysis of Temozolomide,
we are going to estimate the constant k1 of the Skipper model as an academic value to illustrate
the theoretical results (its estimation is in itself a complex problem). Let’s consider the minimum
dose that is applied in treatments, 50 mg/m2, and 2 mg/m2 as a dose that has no effect on the
body. Then, considering the male’s and women’s BSA, and the distribution volume (VD = 0.4
L/kg), we can make the following reasoning:
Be c the concentration of the drug in the body at the instant of time t1, and d1 the dose given at
t1. Let’s consider a man with a weight β = 80 kg. If the tumor volume decreases with doses of 50
mg/m2, then by (2.5), (1−k1c) < 0. Note that by (2.2) we get that c = d1σ =
d1α
vDβ
= 2.96875 ≈ 3






. In the same way, if the volume of




mg/L, in this case k1 <
1
0.11875
≈ 8.42. Then we get the following interval: k1 ∈ (0.33, 8.42).
For the case of a woman (β = 60 kg) we can make an analogous reasoning, so in this case we get:
k1 ∈ (0.3, 7.5). Finally, for our numerical experiments we will take k1 = 3.
We are going to study what is the total dose given in each usual treatment of Temozolomide, and
what is the final size of the tumor at time T , considering a study period of 28 days (from 0 to 27),
T = 29 (two days after the end of the treatment), L0 = 0.03 and that the patient is a woman (so
the final total dose given is always multiplied by 1.6). As an illustration, we are going to compare
the results for each treatment taking k1 = 3 and ξ = 0.00551. In Table 3.1 we show the results
obtained, and in Figure 3.2 the graphic representation of the evolution of the tumor with each
treatment.
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L(T) Total dose
Treatment 1 0.0345 1000 mg/m2
Treatment 2 0.0215 2100 mg/m2
Treatment 3 0.0215 2100 mg/m2
Treatment 4 0.0272 1575 mg/m2
Treatment 5 0.0293 1400 mg/m2
Table 3.1: Results obtained for each treatment of Temozolomide and the Skipper model.
Figure 3.2: Tumor’s size evolution with the five treatments.
Note that in treatments 2 and 3, the same total dose is given, and the tumor volume has been
reduced to the same size (see rows 2 and 3 of Table 3.1). This exemplifies what was seen in Section
3.1, because in this case λ >> 0. Furthermore, there is not a great reduction in the volume of the
tumor, because if k1 is small, it means that the human organism has a high resistance to the drug.
In relation to problem (P̂2) defined in (2.10), assuming that times have no influence, and using what
we saw while studying problem (P2S), we have used the total dose so that the bound γ is satisfied
in two different ways, with the five treatments considered for Temozolomide. Experimentally we
have made the calculations assuming that the patient is a woman of 60 kg, the initial size of the
tumor is 0.3 and we do not want it to be greater than 0.5 at the final time T = 365. We have also















)) = −100.2068 and σ = 1.6
24
. Then, γ =
λ
k1σ
(T + γ̃) = 12236.09.
• CASE 1: Fixed the final time of treatment T and a maximum tumor volume that we do
not want to exceed (L∗) we are going to compare the possible treatments, with di = d,
∀i ∈ {1, ..., N}. In this way we are going to study how often each dose of Temozolomide
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should be given (d = 200, 150, 100, 75 or 50 mg/m2).
To this end we are going to take into account that the sum of the doses {di}Ni=1 must
be greater or equal than γ = 12236.09. As an example, if all doses are of 200 mg/m2,
N ≥ d12236.09/200e = 62. Since we are interested in minimizing the total dose, we take
N = 62. As the time period under study is 365 days, each dose should be given every
b365/62c = 5 days (where bxc denotes the largest integer that does not exceed x). We
proceed in the same way with the other possible doses, and obtain the results of the second
column of Table 3.2, Also, in that table we show the results obtained: the total dose given
and the value of L(T ), and in Figure 3.3 we can see the evolution of the tumor size for each
case.
Dose Frequency Total dose L(T)
200 mg/m2 62 doses given, every 5 days 12400 mg/m2 0.4913
150 mg/m2 82 doses given, every 4 days 12300 mg/m2 0.4954
100 mg/m2 123 doses given, every 2 days 12300 mg/m2 0.4954
75 mg/m2 164 doses given, every 2 days 12300 mg/m2 0.4954
50 mg/m2 245 doses given, every day 12250 mg/m2 0.4975
Table 3.2: Results obtained for each treatment in CASE 1 with Temozolomide.
Figure 3.3: Evolution of the tumor size for each case of Table 3.2.
Conclusions: In the first row of Table 3.2, 200 mg/m2 doses are given every five days during
62 cycles, and the tumor reaches the smallest volume. However this case is not very safe in
terms of toxicity: we know that a usual treatment in which 200 mg/m2 dose are given is
carried out for 5 days in a row, and with 23 days off, so it is not clear that it is safe to give
that dose it every 5 days. On the other hand, the most reasonable treatment seems to be the
fifth, because the maximum allowed tumor size is not exceeded and 50 mg/m2 dose will be
given every day during a period of 245 days with 120 days off (metronomic chemotherapy),
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which is reasonable in regards to toxicity because usually, in treatment 5, 50 mg/m2 dose
are given daily. In this instance the final tumor size would be 0.4979. Furthermore, Table
3.2 shows that the reduction in size of the tumor only depends on the total dose given: the
higher the total dose, the lower the final tumor size. Also, we can see that in those cases
where the same total dose is given (see the rows 2, 3 and 4 of the Table 3.2), the same value
of L(T ) is reached.
• CASE 2: In this case, we are going to estimate how long each treatment should be carried
out minimizing the dose given, but without exceeding the maximum tumor volume at the
time T , L∗ = 0.5.
Now let’s consider the treatments in Figure 3.1 and the number of doses exposed in the
second column of Table 3.2. If we use Treatment 1, taking into account that we need to give
62 doses of 200 mg/m2 to satisfy the restriction, and that 5 doses are given in each cycle,
then 12 cycles and 2 more days (338 days) are needed. Proceeding in a similar way with the
rest of the treatments, we obtain the duration of each one of them so that L(T ) ≤ L∗. We
show the results in the last column of Table 3.3.
Dose Duration
Treatment 1 200 mg/m2 338 days
Treatment 2 150 mg/m2 152 days
Treatment 3 100 mg/m2 158 days
Treatment 4 75 mg/m2 213 days
Treatment 5 50 mg/m2 245 days
Table 3.3: Results obtained in CASE 2 with Temozolomide.
Conclusions: In Table 3.3 we observe that when the doses given are between 100 and 150
mg/m2 we get the shortest treatment times. In this case, these two seem the most interesting,
since they respect toxicity criteria (being treatments that are commonly used), verify that
the volume L∗ = 0.5 of the tumor is not exceed, and they are the ones which require less
treatment time. It is therefore noted that in this case the therapy that seems to be most
recommended is not MTD therapy, but smaller doses with less spacing.
3.4 Cabazitaxel
The drug Cabazitaxel is used to treat people with prostate cancer. It belongs to a group of
anticancer drugs known as taxanes. These types of drugs prevent cell growth by stopping the
cells from dividing. Its half life is about 95 hours and its volume of distribution (VD) is 4.864 L
(see [17]). It is administered intravenously, and the dose varies depending on the patient’s body
surface, as in the case of Temozolomide. There are numerous studies on the dose that should
be administered, and there are three common treatments which depend on the possible adverse
reactions that may occur (see [15]):
• Treatment 1: 25 mg/m2 administered for 1 hour intravenously every 3 weeks. It is the
most common treatment.
• Treatment 2: 20 mg/m2 administered for 1 hour intravenously every 3 weeks. This
treatment is administered in case of adverse reactions.
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• Treatment 3: 15 mg/m2 administered for 1 hour intravenously every 3 weeks. This
treatment is administered in case the adverse reactions continue after treatment 2.
As we have seen, its half-life is 95 hours (3.96 days), which we can use to estimate the value λ of
(2.1) as follows:




−λt̃ =⇒ λ = log(2)
t̃
≈ 0.175 days−1.
In a similarly way to the case of Temozolomide, we are going to take ξ = 0.00551 on equation
(2.3). Also, we have taken this value based on the one calculated in experimental studies for drugs
with long half-life. See, for example [11], where a value ξ = 0.0075 is obtained for a drug with long
half-life: Bevacizumab.
In order to estimate the value of the constant k1 of the Skipper model, note that there is not usual
to give doses of less than 10 mg/m2. Then, considering that the minimum dose that is applied
in treatments is 10 mg/m2 and 2 mg/m2 as a dose that has no effect on the body, and making
a reasoning analogous to that of Temozolomide, we take as theoretical value k1 = 1.2 for women
and k1 = 1 for men.
We are going to study the 3 treatments exposed previously, and another case that although it’s not
medically used, serves us to check the results of the Section 3.1 numerically. We want to compare
two different treatments but in which the same total dose is given. Therefore, we introduce a
fourth treatment in which 10 mg/m2 dose is administrated every week, so in this treatment the
same cumulative dose is given as in treatment 2. Then, let’s consider a period of time of 28 days,
T = 29, L0 = 0.03, and that the patient is a male (so the total dose given will be multiplied by
1.9 and k1 = 1). In Figure 3.4 and in Table 3.4 we can see the comparison of these 4 treatments.
Figure 3.4: Tumor volume evolution with the four treatments of Cabazitaxel.
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Dose Frecuency Total dose L(T)
25 mg/m2 Every 3 weeks 50 mg/m2 0.0056
20 mg/m2 Every 3 weeks 40 mg/m2 0.0097
15 mg/m2 Every 3 weeks 30 mg/m2 0.0157
10 mg/m2 Once a week 40 mg/m2 0.0092
Table 3.4: Results obtained for each treatment of Cabazitaxel with the Skipper model.
In the case of this drug, in which the value of λ is small (λ = 0.175), and taking T = 29, a small
value for λT is obtained. Then, we can observe (as we saw in Section 3.1) that although the total
dose given in treatments 2 and 4 is the same, we don’t get the same value for the final volume of
the tumor (see rows 2 and 3 of Table 3.4).
Now, let’s study the problem (P̂2) by considering the same two cases which we studied for the
Temozolomide. Again we are going to assume that the times have no influence. Be L0 = 0.3,
L∗ = 0.5, k1 = 1 (considering that the patient is a male), ξ = 0.00551, and T = 365, then
γ = 118.63.
• CASE 1: For the 3 possible doses, 25, 20 and 15 mg/m2, we are going to see how many and
how often they should be administered during a year so that the final volume of the tumor
is less than L∗ = 0.5. To this end, we have carried out a process analogous to that of the
Temozolomide case. In Figure 3.5 we can see the evolution of the volume of the tumor in
each case and in the Table 3.5 the results obtained.
Figure 3.5: Evolution of the tumor size for each treatment of Cabazitaxel using the assumptions
of case 1.
Dose Frequency Total dose L(T)
25 mg/m2 5 doses given, every 73 days 125 mg/m2 0.47057
20 mg/m2 6 doses given, every 60 days 120 mg/m2 0.49221
15 mg/m2 8 doses given, every 45 days 120 mg/m2 0.49222
Table 3.5: Results obtained for each treatment in CASE 1 with Cabazitaxel.
Conclusions: As expected, the case that produces the best results is the one in which
the total dose administered is higher (see the first row of Table 3.5). On the other hand,
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we cannot be sure that these three treatments are effective in practice due to the spacing
between doses. Therefore, the treatment that produces the best results is a dose of 25 mg/m2
every 73 days (only 5 mg/m2 more are given in total respect the other two cases). Note that
now, although the value of λ is small, λT >> 0, so there is a great similarity in the final
result (L(T )) of the two cases where the same total dose is given (see rows 2 and 3 of Table
3.5).
• CASE 2: For the 3 possible treatments, we’re going to study what the duration of these
would be so that the final size of the tumor at T = 365 is less than L∗ = 0.5. Note that in
all the cases, a dose is given every 3 weeks. Figure 3.6 represents the evolution of the size of
the tumor over a year, and Table 3.6 shows the duration of each treatment and the results
obtained.
Figure 3.6: Tumor size evolution for each treatment of Cabazitaxel with the assumptions of the
case 2.
Dose Duration L(T)
Treatment 1 25 mg/m2 105 days 0.47057
Treatment 2 20 mg/m2 126 days 0.49221
Treatment 3 15 mg/m2 168 days 0.49221
Table 3.6: Results obtained for each treatment in CASE 2 with Cabazitaxel.
Conclusions: Again, the treatment that produces the best results is the one in which
a higher total dose is given and it is also which finishes earlier (first row of Table 3.6).
Although λ is small, as λT >> 0, in both approaches to the problem we arrive to similar
values of L(T ). It is also observed that the best results are not produced by the treatment
that ends later (the same as in the case of Temozolomide).
To conclude this chapter, let’s see why we have decided to consider in the numerical simulations
t1 = 0 with a simple two variable example. As in all the cases under study, let’s consider 0 ≤ t1 <










subject to d1 + d2 = D,
dmin ≤ d1, d2 ≤ dmax,
⇐⇒








subject to dmin ≤ d1, d2 ≤ dmax,
⇐⇒







subject to dmin ≤ d1, d2 ≤ dmax,
t1=0⇐⇒
{
Min d1 + (D − d1)eλt2
d1, d2 ∈ [dmin, dmax] ∩ [D − dmax, D − dmin]
.
Note that in the last equivalence we are taking t1 = 0 the minimum possible value, since our
interest is to reduce the volume of the tumor as much as possible.
On the other hand, let’s see an example in which the conclusions of Theorem 3.1.2 are not true
in the case where the values of the times {ti}Ni=1 are not fixed from the beginning. This does not
contradict the theorem, since in the hypotheses that led us to state it, we counted on fixed times.
With Example 3.4.1 we want to emphasize why we had fixed them initially:
Example 3.4.1. Be N = 2, λ = 1, dmin = 1 mg/m
2, dmax = 9 mg/m
2, D = 10 mg/m2. Let’s
solve the problem (P1S) without considering the times initially fixed.
From Theorem 3.1.2, we would consider taking d = (9, 1). As in this case we do not consider fixed
times, we must estimate t1 and t2. From what was seen before t1 = 0, and as the dose d1 is big,
we can consider, for example, t2 = 3 (3 days between each dose), and the cost functional of the
problem would be approximately 29.
Let’s consider the case where we start with the lowest dose. That is, d = (1, 9). Again we take
t1 = 0, but now, as the first dose is small, we could consider that one day of spacing is enough,
and therefore t2 = 1. In this way the cost functional of the problem becomes approximately 25.5.
This shows that the hypothesis of having fixed times is absolutely necessary in Theorem 3.1.2.
Chapter 4
Emax model
For the Emax model, we consider ρ̃(t) =
k1c(t)
k2 + c(t)
in (2.5), with given k1, k2 > 0, and c(t) as we
have defined in (2.2).


























k̂2 + e−λs(d1eλt1 + d2eλt2)
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λt1 + · · ·+ dNeλtN )

















d1eλ(t1−t2) + d2 + k̂2
)






λ(t1−tN ) + · · ·+ dN−1eλ(tN−1−tN ) + k̂2








λ(t1−T ) + · · ·+ dNeλ(tN−T ) + k̂2








(d1 + k̂2) · · · (d1eλ(t1−tN ) + · · ·+ dN−1eλ(tN−1−tN ) + dN + k̂2)
(d1eλ(t1−t2) + k̂2) · · · (d1eλ(t1−T ) + · · ·+ dNeλ(tN−T ) + k̂2)
)
= F (N, d)
(4.1)
Then, using (2.7) we get the following expression for L(T ):







exp (−ξ (T − k1F (N, d)))
)
. (4.2)
4.1 Minimizing the tumor volume with a fixed cumulative dose
As in the case of the Skipper model, first of all we want to minimize the tumor volume: problem
(P̂1) defined in Section 2.3. As we saw in that section, it is equivalent to maximize F (N, d):
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(P1E)

Max F (N, d)





dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N},
. (4.3)
In this problem, we have N + 1 variables to determine: N , di, ∀i ∈ {1, . . . , N}. As in the previous
cases, the values of T , D, dmin dmax and ti, ∀i ∈ {1, . . . , N} are fixed. Also, the objective function
is nonlinear. To study (P1E) we are going to consider two cases: λ >> 0 and λ ≈ 0.
4.1.1 Case 1: λ >> 0
Let’s start by studying a simple case, in which λ >> 0 (for example the case of Temozolomide).
Here, the times ti do not seem to play a relevant role, because as T > ti, ∀i ∈ {1, . . . , N}, λT >> 0,
then eλ(ti−T ) ≈ 0 and eλ(ti−tj) ≈ 0, ∀i, j ∈ {1, . . . , N}, j > i. Therefore, we can take:
















(di + k̂2), so we get the problem (P 1E):
(P 1E)










dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}.
.
Once more, this is a mixed nonlinear optimization problem, and we have to determine the value
of N + 1 variables: N and {di}Ni=1.








∩ N, then there is a solution for (P 1E).






∩N. Then, fixed the value
of N , the set of restrictions of the problem is nonempty and compact (it’s the same of problem
(PN1S), see the proof of Theorem 3.1.2). Then, as the function f3 is continuous in the variable d
(for N fixed) there is a global solution to the problem (P 1E) (see Appendix A).
It is a well known result the following relation between the geometric and arithmetic means:
Proposition 4.1.1. The arithmetic mean of a set of positive numbers (di ∈ R+, i ∈ {1, . . . , N}) is










We only obtain the equality when di = dj, ∀i, j ∈ {1, . . . , N}.
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Proof. See Proposition B.0.1 in Appendix B.





















Therefore, by (4.5) the maximum of (P 1E) with N fixed is reached when di =
D
N
, ∀i ∈ {1, . . . , N}.
Now we want to study the dependence on N . To do this we are interested in studying the function
f4 defined below. In the following we will write x instead of N , but we are only interested in the
values of x ∈ N.
For simplicity, we will consider the case where D is a natural multiple of dmin and dmax, that is:
D = N1 dmax = N2 dmin, with dmin > 0 and N1, N2 ∈ N.
(P4)






subject to x ∈ [N1, N2] ∩ N.
.
Let’s study the growth of the function f4(x) for different values of k̂2. By hypothesis of the Emax














D + k̂2 x
)
.
To see the behavior of function f4, in Figure 4.1 we represent its graph for D = 100 and k̂2 ∈
[0.3, 0.5], k̂2 ∈ [1, 1.2]:
Figure 4.1: Graphic of f4(x) for different values of k̂2.
Let’s study the positive roots of f ′4(x):

































































− 1 = W (−k̂2/e)⇐⇒
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⇐⇒ D
x
+ k̂2 = e
W (−k̂2/e)+1 ⇐⇒ x = D
eW (−k̂2/e)+1 − k̂2
, (4.6)
where W is the Lambert W function (see Appendix C). Let’s see what branch of Lambert’s W
function we should consider:
x > 0⇐⇒ eW (−k̂2/e)+1 > k̂2 ⇐⇒W (−k̂2/e) > log(k̂2/e)
r=k̂2/e⇐⇒ W (−r) > log(r)
In Figure 4.2 we show the graphs of W (−r) and log(r), and we see that W (−r) > log(r) if and
only if r ∈ (0, 1/e) (so, as r = k̂2/e, k̂2 ∈ (0, 1)), then with W we represent the branch W0 of the
W Lambert function:
Figure 4.2: Graphs of W (−r) and log(r).
Then, we distinguish two cases:
• k̂2 ≥ 1. As x > 0 and D > 0, the function f4 is strictly increasing because it has no real








= log(k̂2) and lim
x→+∞
D
D + k̂2 x
=
0 < log(k̂2).
Then, the solution of (P4) is N2 =
D
dmin
, and (N2, (dmin, . . . , dmin)︸ ︷︷ ︸
N2
) is the solution of (P 1E)
(Metronomic chemotherapy).
• 0 < k̂2 < 1. As x > 0, f ′4(x) has one positive root x = DeW (−k̂2/e)+1−k̂2 then:
– If x < x̄ the function f4 increases.
– If x > x̄ the function f4 decreases.
As the maximum of f4 is reached at x̄ =
D
eW (−k̂2/e)+1 − k̂2
let’s study the solution of (P4)
and (P 1E):
– If eW (−k̂2/e)+1 − k̂2 ≥ dmax, then N1 =
D
dmax
is the solution of (P4), and the solution of
(P 1E) is (N1 (dmax, . . . , dmax)︸ ︷︷ ︸
N1
) (MTD therapy).
– If eW (−k̂2/e)+1 − k̂2 ≤ dmin, then N2 =
D
dmin
is the solution of (P4), and the solution of
(P 1E) is (N2, (dmin, . . . , dmin)︸ ︷︷ ︸
N2
) (Metronomic chemotherapy).
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– If dmin ≤ eW (−k̂2/e)+1 − k̂2 ≤ dmax then N3 ∈ N such as f4(N3) ≥ f4(N) for each











 is the solution of
(P 1E), where N3 = bx̄c or N3 = dx̄e.
Let’s see an example where we can observe the variation in the solution of the problem (P 1E)
according to the value of k̂2:
Example 4.1.1. Let’s set a value for D, dmin, dmax and vary the value of k̂2 to see how the
optimal treatment changes according to the value of this constant. Be z = eW (−k̂2/e)+1 − k̂2:
a) Be D = 1000 mg/m2, dmin = 50 mg/m
2 and dmax = 200 mg/m
2. This is a realistic example
for the case of the Temozolomide.
– If k̂2 = 0.2, z = 2.31 < dmin, so N = 20, di = dmin = 50 mg/m
2, i = 1, . . . , N .
– If k̂2 = 0.5, z = 1.66 < dmin, so N = 20, di = dmin = 50 mg/m
2, i = 1, . . . , N .
– If k̂2 ≥ 1, f ′4(x) has no real roots, so we get that again N = 20, di = dmin = 50 mg/m2,
i = 1, . . . , N .
In view of the treatment 1 defined in Figure 3.1, in the three cases t = (1, 2, 3, . . . , 20), so the
treatment that seems most reasonable is metronomic chemotherapy.
b) Be D = 100 mg/m2, dmin = 2 mg/m
2 and dmax = 10 mg/m
2. This is not a realistic
example.
– If k̂2 = 0.2, z ∈ (dmin, dmax), so N = 43, di = 2.33 mg/m2, i = 1, . . . , N .
– If k̂2 = 0.5, z < dmin, so N = 50, di = dmin = 2 mg/m
2, i = 1, . . . , N .
– If k̂2 ≥ 1, f ′4(x) has no real roots, so N = 50 and di = dmin = 2 mg/m2, i = 1, . . . , N .
In this example, when k̂2 ≥ 0.5 the treatment that seems to be most effective is metronomic
chemotherapy. Note that taking into account the interpretation of k̂2 (whih will be explained
in Section 4.3), usually k̂2 > 1.
4.1.2 Case 2: λ ≈ 0








λ(t1−t2) + d2 + k̂2
d1eλ(t1−t3) + d2eλ(t2−t3) + k̂2
)




λ(t1−tN ) + · · ·+ dN + k̂2
d1eλ(t1−T ) + · · ·+ dNeλ(tN−T ) + k̂2
)
.
Let’s consider the case of drugs with long half-life (λ ≈ 0). By (4.1), lim
λ→0







and let’s apply L’Hopital’s rule:
lim
λ→0
h′(λ) =(t2 − t1)
d1
d1 + k̂2
− (t2 − t1)
d1
d1 + d2 + k̂2
+ (t3 − t1)
d1
d1 + d2 + k̂2
+
+ (t3 − t2)
d1 + d2
d1 + d2 + k̂2
+ · · ·+ d1(t1 − tN ) + · · ·+ dN−1(tN−1 − tN )
d1 + · · ·+ dN + k̂2
−
− d1(t1 − T )− · · · − dN (tN − T )
d1 + · · ·+ dN + k̂2
=
= (t2 − t1)
d1
d1 + k̂2
+ (t3 − t2)
d1 + d2
d1 + d2 + k̂2
+ · · ·+ (T − tN )
d1 + · · ·+ dN
d1 + · · ·+ dN + k̂2
.
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Therefore, we can consider the following optimization problem to minimize L(T ), with N variable:
(P̃1E)

Min f̃5(N, d) = −
(t2 − t1)d1
d1 + k2
− (t3 − t2)(d1 + d2)
d1 + d2 + k2
− · · · − (T − tN )(d1 + · · ·+ dN )
d1 + · · ·+ dN + k2





dmin ≤ di ≤ dmax, ∀i ∈ {1, ..., N}.
.
For simplicity, let us begin by stating the problem (P̃1E) in the case N = 3 fixed, and considering
wi = (ti+1− ti), i ∈ {1, 2}. We can reduce it to a 2 variable problem because as w3 = (T − t3) and
d1 + d2 + d3 = D, then the last term is constant. Also, using the equality constraint, we get:
(P̃ 31E)

Min f35 (d) = −
w1d1
d1 + k̂2
− w2(d1 + d2)
d1 + d2 + k̂2
d ∈ R2
subject to D − dmax ≤ d1 + d2 ≤ D − dmin
dmin ≤ di ≤ dmax, ∀i ∈ {1, 2}.
.
















As w1, w2, k̂2 > 0 and d1, d2 > 0, then z
T [∇2f35 (d)]z > 0, ∀z ∈ R2\{0}, and ∇2f35 (d) is a positive
definite matrix. Therefore, as f35 (d) is strictly convex and the set of restrictions is convex (because
the restrictions are linear), the problem (P̃ 31E) has only one solution (see, for instance [2]).
Let’s see in Figure 4.3 an example of the graphical representation of this problem, with w1, w2 = 1,
k̂2 = 1, dmin = 1, dmax = 3 and D = 4.
Figure 4.3: Example of problem (P̃ 31E).
Let’s come back to problem (P̃1E) and now, we are going to study it in the case of N fixed and
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with wi = (ti+1 − ti), i ∈ {1, . . . , N − 1}, wN = (T − tN ):
(P̃N1E)

Min f5(d) = −
w1d1
d1 + k̂2
− w2(d1 + d2)
d1 + d2 + k̂2
− · · · − wN−1(d1 + · · ·+ dN−1)
d1 + · · ·+ dN−1 + k̂2
− wN (d1 + · · ·+ dN )






dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N − 1}.
.




di = D, the term
wN (d1 + · · ·+ dN )




Min f5(d) = −
w1d1
d1 + k̂2
− w2(d1 + d2)
d1 + d2 + k̂2
− · · · − wN−1(d1 + · · ·+ dN−1)
d1 + · · ·+ dN−1 + k̂2
d ∈ RN−1
subject to D − dmax ≤
N−1∑
i=1
di ≤ D − dmin,
dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N − 1}.
.
However, for simplicity, in order to study the existence of a unique solution and its structure, we
are going to consider the problem (P̃N1E).








∩ N, then there is a unique solution for
(P̃N1E).
Proof. The proof of the existence of solution is analogous to the proof of Theorem 3.1.1. The
uniqueness of the solution follows from the fact that f5 is strictly convex.
Theorem 4.1.3. Under the hypotheses of Theorem 4.1.2, the unique solution to the problem (P̃N1E)
is given by:








3. (dmax, . . . , dmax, d
∗, dmin, . . . , dmin) if
D
dmax
< N < Ddmin , N ∈ N. with d
∗ verifying dmin ≤
d∗ ≤ dmax. The number of dmin and dmax doses can be between 0 and N − 1. If m is the
number of dmin, then d
∗ = D + (dmax − dmin)m− (N − 1)dmax.
Proof. Let’s study the different possible cases:
1. If N = Ddmin ∈ N, then d = (dmin, . . . , dmin) is the solution of the problem because it’s the
unique feasible point.
2. If N = Ddmax ∈ N, then d = (dmax, . . . , dmax) is the solution of the problem because it’s the
unique feasible point.
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Be j0 = N−m the position of d∗ ∈ [dmin, dmax], then d = (dmax, . . . , dmax︸ ︷︷ ︸
N−m−1
, d∗, dmin, . . . , dmin︸ ︷︷ ︸
m
)
is a Kuhn-Tucker point (see [2]):













2. µi(di − dmax) = 0, ∀i ∈ {1, . . . , N}.
µ̂i(−di + dmin) = 0, ∀i ∈ {1, . . . , N}.
µi, µ̂i ≥ 0, ∀i ∈ {1, . . . , N}.
3. The point verifying the two previous conditions must also be feasible.
In this case we can take λ = −(∇f5(d))j0 (λ is positive), and taking in account that
(∇f5(d))i − (∇f5(d))j > 0 if i > j:
– If i < j0, µ̂i = 0 and µi = −(∇f5(d))i − λ > 0.
– If i = j0, µ̂i = 0 and µ̂i = 0.
– If i > j0, µi = 0 and µ̂i = (∇f5(d))i + λ > 0.
Let’s calculate m: Using D = m dmin + (N −m− 1)dmax + d∗, it follows that dmin ≤ d∗ =
D + (dmax − dmin)m− (N − 1)dmax ≤ dmax, then:
Ndmax −D
dmax − dmin
− 1 ≤ m ≤ Ndmax −D
dmax − dmin
(4.7)
Therefore, m is the greater integer which verifies (4.7).
Finally, as f5 is strictly convex and the set of restrictions is convex, then if d is a Kuhn-Tucker
point it is the solution to (P̃N1E) (see [2]).
Let’s see an example in which we solve (P̃N1E) using the previous theorem for different values of N :
Example 4.1.2. Be D = 1050 mg/m2, dmin = 100 mg/m
2, dmax = 200 mg/m
2. Then, let’s
solve (P̃N1E) for N ∈ [6, 10]:
• If N = 6, m ∈ [0.5, 1.5] and we take m = 1. Then, d = (200, 200, 200, 200, 150, 100).
• If N = 7, m ∈ [2.5, 3.5] and we take m = 3, so d = (200, 200, 200, 150, 100, 100, 100︸ ︷︷ ︸
3
).
• If N = 8, m ∈ [4.5, 5.5] so m = 5, and d = (200, 200, 150, 100, . . . , 100︸ ︷︷ ︸
5
).
• If N = 9, m ∈ [6.5, 7.5] so m = 7, and d = (200, 150, 100, . . . , 100︸ ︷︷ ︸
7
).
• If N = 10, m ∈ [8.5, 9.5] so m = 9, and d = (150, 100, . . . , 100︸ ︷︷ ︸
9
).
Note that in all the previous cases, there is a dose d∗ = 150 mg/m2 in the position N−m. Finally,
in order to solve the problem (P̃1E) we need to know the times (fixed a priori) and the value of k̂2
and keep the tuple (N, d) which minimizes f̃5(N, d).
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4.2 Minimizing the cumulative dose and keeping the tumor size
below a level
We will start by considering the problem (P̂2) defined in Section 2.3. In this problem we want to
minimize the total dose given but preserving the volume of the tumor at time T not to exceed an
established bound L∗.
As we are studying the Emax model,
∫ T
0
ρ̃(t)dt = k1F (N, d), with F given in (4.1). Then, we
have to preserve the following lower bound:
log
(
(d1 + k̂2) · · · (d1eλ(t1−tN ) + · · ·+ dN−1eλ(tN−1−tN ) + dN + k̂2)














N ∈ N, d ∈ RN
subject to
(d1 + k̂2) · · · (d1eλ(t1−tN ) + · · ·+ dN + k̂2)
(d1eλ(t1−t2) + k̂2) · · · (d1eλ(t1−T ) + · · ·+ dNeλ(tN−T ) + k̂2)
≥ eγ ,
dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}.
.
with γ as defined above. Again, in this problem both N and each di are variables. As in Section
4.1, we are going to distinguish 2 cases to study this problem: λ >> 0 and λ ≈ 0.
4.2.1 Case 1: λ >> 0
Let’s start by studying the case in which λ >> 0. Then, as T > ti, ∀i ∈ {1, . . . , N}, eλ(ti−T ) ≈ 0
and eλ(ti−tj) ≈ 0, ∀i, j ∈ {1, . . . , N}, j > i. Be γ = λ
k1
(T + γ̃), therefore, we get:
L(T ) ≤ L∗ ⇐⇒
(d1 + k̂2) · · · (dN−1 + k̂2)(dN + k̂2)
k̂N2
≥ eγ .
Then the problem (P2E) is formulated as follows:
(P 2E)









(di + k̂2) ≥ eγ k̂N2
dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}.
.
First, note that the set of feasible N values is infinite, but only a finite number of N have practical
interest: There is a value N̂ ∈ N large enough so that (dmin + k̂2)N̂ ≥ eγ k̂N̂2 . Of course, there
is no point in considering larger values, since if N > N̂ , then f̃(N̂ , d̂) = N̂dmin < f̃(N, d) for
d̂ = (dmin, . . . , dmin) and for all (N, d) feasible for (P 2E). Using di ≤ dmax, ∀i ∈ {1, . . . , N}, we
get the following lower bound for N :
N∏
i=1
(dmax + k̂2) ≥
N∏
i=1
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≥ eγ/N k̂2 ⇐⇒
N∑
i=1
di ≥ Nk̂2(eγ/N − 1) .




γ/N − 1) and di = dj , ∀i, j ∈
{1, . . . , N}, i 6= j, by Proposition 4.1.1, and d̄i = k̂2(eγ/N − 1), ∀i ∈ {1, . . . , N}, when this point is
feasible.
Imposing that d̄i ≥ dmin, ∀i ∈ {1, . . . , N}, then eγ/N ≥
dmin + k̂2
k̂2






Therefore, let’s consider the following optimization problem in one variable in order to estimate
the optimum value of N . We will write x instead of N for simplicity, but we are only interested














Min f6(x) = xk̂2(e
γ/x − 1)
subject to x ∈ [N1, N2] ∩ N.
.
The function f6(x) is strictly decreasing for x > 0, let’s see its graphic for γ = 5 > 1, γ = 0.5 < 1
and in both cases k̂2 = 100:
Figure 4.4: Graphic of f6(x) for k̂2 = 100 and γ = 5 (left), γ = 0.5 (right).
Note that f ′6(x) =
k̂2
x
(eγ/x(x− γ)− x) has no real roots for x > 0, and f ′6(x) < 0, ∀x > 0:


























= −1 (see Appendix C),
so it must be
γ
x
= 0, and we get a contradiction because γ > 0. Then, as f ′6(x) has no real roots
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for x > 0, and f ′6(1) < 0, we get that f
′
6(x) < 0, ∀x > 0. Therefore, f6(x) is strictly decreasing for
all x > 0, so the solution to (P6) will be x = bN2c.
Coming back to problem (P 2E), as we want to minimize the cumulative dose, we will take
d = (k̂2(e
γ/N − 1), . . . , k̂2(eγ/N − 1︸ ︷︷ ︸
N








Let’s look at an example where we check that the expected result is obtained:
Example 4.2.1. Be γ = 6, k̂2 = 100, dmin = 75 mg/m
2 and dmax = 200 mg/m
2. Let’s solve
(P 2E).





) = 6log(1.75) = 10.72. Note that
there are 5 possible values of N : 6, 7, 8, 9, 10:
• If N = 6, d(6) = (171.83, . . . , 171.83︸ ︷︷ ︸
6
) and f̃(6, d
(6)
) = 1030.98.
• If N = 7, d(7) = (135.64, . . . , 135.64︸ ︷︷ ︸
7
) and f̃(7, d
(7)
) = 949.48.
• If N = 8, d(8) = (111, 70, . . . , 111, 70︸ ︷︷ ︸
8
) and f̃(8, d
(8)
) = 893.60.
• If N = 9, d(9) = (94.77, . . . , 94.77︸ ︷︷ ︸
9
) and f̃(9, d
(9)
) = 852.93.
• If N = 10, d(10) = (82.21, . . . , 82.21︸ ︷︷ ︸
10
) and f̃(10, d
(10)
) = 822.11.







 = ⌊ 6log(1.75)⌋ = 10
and di = k̂2(e
γ/N − 1) = 100(e6/10 − 1) = 82.21, ∀i ∈ {1, . . . , 10}.
4.2.2 Case 2: λ ≈ 0
Now let’s consider the case in which λ ≈ 0. Then, eλ(ti−T ) ≈ 1 and eλ(ti−tj) ≈ 1, ∀i, j ∈
{1, . . . , N}, j > i. We are going to consider the same function h(λ) as in subsection 4.1.2. Again:
lim
λ→0







, and applying L’Hopital’s rule we know that:
lim
λ→0
h′(λ) = (t2 − t1)
d1
d1 + k̂2
+ (t3 − t2)
d1 + d2
d1 + d2 + k̂2
+ · · ·+ (T − tN )
d1 + · · ·+ dN
d1 + · · ·+ dN + k̂2
.
Therefore, combining (2.12) and (4.8) we get




(t3 − t2)(d1 + d2)
d1 + d2 + k̂2
+ · · ·+ (T − tN )(d1 + · · ·+ dN )
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In this case the problem (P2E) is formulated as follows for N fixed:
(P̃N2E)










(t3 − t2)(d1 + d2)
d1 + d2 + k̂2
+ · · ·+ (T − tN )(d1 + · · ·+ dN )
d1 + · · ·+ dN + k̂2
≥ γ
dmin ≤ di ≤ dmax, ∀i ∈ {1, . . . , N}.
.
In general, we think that this problem is very complex to be solved explicitly; however, the fact of
having it formulated helps us to be able to compare several treatments: check if they are admissible
under the conditions of the problem, and which would produce better results. Let’s look at an
example:




(t3 − t2)(d1 + d2)
d1 + d2 + k̂2
+
· · ·+ (T − tN )(d1 + · · ·+ dN )
d1 + · · ·+ dN + k̂2
. We want to study the following three treatments:
• Treatment 1: t̃ = (0, 1, 2, . . . , 9) and d̃ = (10, 10, 10, . . . , 10). We can check that g(t̃, d̃) =
25.96 ≥ γ, and fN2 (d̃) = 100.
• Treatment 2: t̂ = (0, 1, 2, . . . , 9) and d̂ = (7, 7, 7, . . . , 7). We can check that g(t̂, d̂) =
25.23 ≥ γ, and fN2 (d̂) = 70.
• Treatment 3: t = (10, 11, . . . , 19, 20) and d = (10, 10, 10, . . . , 10). We can check that
g(t, d) = 16.44 < γ, so this treatment is not feasible under the conditions of the statement
and the problem (P̃N2E).
In view of Example 4.2.2 we can see all the useful practical information that we can obtain just
from the formulation of the problem. Among the admissible treatments, we can observe which
one minimizes the total dose given (in this case, the second one) verifying the conditions of the
problem. In addition, we can discard those treatments that do not verify the desired conditions
(in this case, treatment 3), without the need for clinical or experimental verification.
4.3 Temozolomide
As we know, Temozolomide is a drug with short half-life, equivalently λ >> 0. Therefore, we are
going to use this drug to check what has been studied in the problems (P 1E) and (P 2E). That
is, we are going to study the problems (P̂1) and (P̂2) in the case of the Emax model and λ >> 0.
Also, we will study the evolution of the tumor volume with the 5 treatments of Temozolomide
exposed in Section 3.3. In order to perform these tasks let’s begin by estimating the value of the
parameters k1 and k2 for this model:




= k1, so we can define the parameter k1 as the maximum effect of the
drug on the body.
• Regarding the constant k2, it can be viewed as the concentration that produces 50% of the






=⇒ 2ĉ = k2 + ĉ =⇒ ĉ = k2.
It is usually noted k2 = EC50 (see, for instance [10]).
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In order to contrast previous results, let’s consider the theoretical values k1 = 45 and k2 = 9. In








Let’s start studying the different value of L(T ) obtained with each treatment. As an example, we
consider that the patient is a woman, L0 = 0.03, N = 28, T = 29, k1 = 9, k2 = 45 and ξ = 0.00551
(the last value is the same as in Section 3.3). In Table 4.1 we can see the results obtained with
each treatment (note that the total dose is multiplied by 1.6 when the patient is a woman), and
in Figure 4.6 the graphic representation of the evolution of the tumor.
L(T) Total dose
Treatment 1 0.0342 1000 mg/m2
Treatment 2 0.0191 2100 mg/m2
Treatment 3 0.0168 2100 mg/m2
Treatment 4 0.0216 1575 mg/m2
Treatment 5 0.0227 1400 mg/m2
Table 4.1: Results obtained for each treatment with Temozolomide.
Figure 4.6: Tumor’s size evolution with the five treatments of Temozolomide.
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Now to study the problem (P̂1) in the case of the Emax model and λ >> 0, we take D = 600
mg/m2, dmin = 50 mg/m
2 and dmax = 200 mg/m
2 (as these values are the maximum and
minimum dose that are administered in the treatments exposed above). We will also consider
T = 25 and that the study period consists on 24 days. We are going to study different types of
treatments with the 5 most common doses, that is, di can be 50, 75, 100, 150 or 200 mg/m
2, and
di = dj , ∀i, j ∈ {1, . . . , N}, i 6= j. As an example we have assumed again that the patient is a
woman, L0 = 0.03, k1 = 45 and k2 = 9. In Table 4.2 we can see the results obtained: the total
number of doses given, and the frequency with which each dose is given:
Dose Frecuency Number of doses L(T)
200 mg/m2 Every 8 days 3 0.0374
150 mg/m2 Every 6 days 4 0.0365
100 mg/m2 Every 4 days 6 0.0354
75 mg/m2 Every 3 days 8 0.0348
50 mg/m2 Every 2 days 12 0.0340
Table 4.2: Results obtained for each treatment with Temozolomide.
As we saw when we studied the problem (P 1E), in this case as λ >> 0 and k2 > 1, the best results
are obtained using metronomic chemotherapy (lower doses with less spacing), see the last row of
Table 4.2.
In order to study problem (P̂2), let’s use the theoretical results obtained for problem (P 2E). As is
Section 3.3, for these experiments we’re going to consider that the patient is a woman, L0 = 0.3,
L∗ = 0.5, a period of a year and T = 365. Again we get that γ̃ = −100.2068, and then, using
k1 = 45, γ = 54.3826. As the patient is woman, and considering k2 = 9 we get k̂2 = 135. For
the 5 usual treatments, we are going to study how many doses should be given and what’s the




≥ eγ , so N ≥ 172.60. Then, 173 doses of 50 mg/m2 should be given during 365
days. Proceeding in the same way with the other treatments we get the following results:
Dose Number of doses given Cumulative dose
200 mg/m2 60 12000 mg/m2
150 mg/m2 73 10950 mg/m2
100 mg/m2 99 9900 mg/m2
75 mg/m2 124 9300 mg/m2
50 mg/m2 173 8650 mg/m2
Table 4.3: Possible treatments of Temozolomide to get L(T ) ≤ L∗.
Again, we can note here that the treatment which minimize the cumulative dose is the one in
which the minimum dose is given (metronomic chemotherapy). The time at which the doses will
be given, which should be fixed, will vary the value of L(T ) obtained, but it will be in any case
less than L∗ as seen in Subsection 4.2.1.
From a different point of view, for the five usual treatments of Temozolomide, we have developed
a program in MATLAB that allows us to know the minimum number of complete cycles that must
CHAPTER 4. EMAX MODEL 39
be carried out to get L(T ) < L∗, and the value of L(T ) obtained for each case. In Table 4.4 we
can see the results obtained, and we can note that, once more, the treatment which minimize the
dose given is that in which lower doses are given (metronomic chemotherapy), as we have proved
in Subsection 4.2.1.
Number of cycles Cumulative dose L(T)
Treatment 1 12 12000 mg/m2 0.4987
Treatment 2 6 12600 mg/m2 0.4198
Treatment 3 5 12600 mg/m2 0.4640
Treatment 4 6 11025 mg/m2 0.4880
Treatment 5 7 9800 mg/m2 0.4297
Table 4.4: Usual treatments of Temozolomide and number of cycles to get L(T ) ≤ L∗.
4.4 Cabazitaxel
To illustrate the theoretical results obtained with respect to drugs with a long half-life, as in the
case of the Skipper model, we will analyze the case of Cabazitaxel. Along this study we have to
consider that the patient is a male.
First of all, we are going to study the 4 treatments which we studied in Section 3.4. To do this,
we have taken a period under study of 4 weeks, with T = 29, k1 = 16, k2 = 8, L0 = 0.03, and that
the patient is a male, so the total dose given will be multiplied by 1.9. In Figure 4.7 we show the
tumor evolution with each treatment and in Table 4.5 the results obtained.
Figure 4.7: Tumor volume evolution with the four treatments of Cabazitaxel with Emax model.
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Dose Frecuency Total dose L(T)
25 mg/m2 Every 3 weeks 50 mg/m2 0.0031
20 mg/m2 Every 3 weeks 40 mg/m2 0.0051
15 mg/m2 Every 3 weeks 30 mg/m2 0.0086
10 mg/m2 Once a week 40 mg/m2 0.0033
Table 4.5: Results obtained for each treatment of Cabazitaxel with the Emax model.
Here, we can appreciate that the best results are obtained the higher the total dose administered.
However, in treatments 2 and 4, the same total dose is given (see rows 2 and 4 of Table 4.5), but
the best results are obtained for the treatment where the doses are given less spaced, that is, a
metronomic treatment.
Now, let’s study some examples as an illustration in order to see what kind of therapy produces
the best results (the lowest value for L(T )) when the same total dose is given (problem (P̃1E)).
First of all, we have taken the same parameters as in the previous example: k1 = 16, k2 = 8,
L0 = 0.03 but with a period of time of 6 weeks and T = 43. In this case, we consider 3 types of
treatments, where in all of them the total dose administered is 50 mg/m2. In the first one, 2 doses
of 25 mg/m2 are given, in the second one 3 doses of 16.67 mg/m2 and in the third one 4 doses of
12.5 mg/m2. We want to estimate what the optimal dose spacing would be for this example.
In Figure 4.8 we can see the graphic representation of the value of L(T ) according to the time
spacing between each given dose. We know that under these conditions the minimum value for
L(T ) is reached when all doses are equal, and furthermore we expect that as k2 > 1, the best
result will be obtained for the lowest dose and with the shortest time spacing (as it can be seen in
Figure 4.8).
Figure 4.8: Tumor’s size at T according to the time spacing between each given dose.
Now, let’s consider that doses of 25 mg/m2 are given during 6 weeks (42 days), every 21 days.
Then, 1 mg/m2 is given every 0.84 days. As the most common doses are 25, 20 and 15 mg/m2,
we are going to study the following cases:
• Treatment 1: 25 mg/m2 every 21 days.
• Treatment 2: 20.24 mg/m2 every 17 days.
• Treatment 3: 15.48 mg/m2 every 13 days.
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In Figure 4.9 we can observe the graphical comparison of these three treatments, and in table 4.6
each value of L(T ).
Figure 4.9: Graphic comparison of Cabazitaxel treatments 1,2,3.
Treatment L(T)
25 mg/m2 every 21 days 0.0023
20.24 mg/m2 every 17 days 0.0011
15.48 mg/m2 every 13 days 0.0012
Table 4.6: Results obtained for each treatment with Cabazitaxel.
The treatments in which lower doses are given, produce the best results (see rows 2 and 3 of Table
4.6).
We are going to end up looking at the problem (P̂2). We know 3 types of treatments (see Section
3.4), so we are going to study how many doses should be given in each case so that after one year
of treatment, if L0 = 0.3, the tumor size does not exceed L∗ = 0.5. In the 3 treatments exposed
in Section 3.4, the spacing between doses is 21 days. In addition, the same dose is given in each
of them during the whole cycle. Let’s take ti+1 − ti = 21, ∀i ∈ {1, . . . , N − 1}. Using MATLAB,
we are going to check what is the minimum number of doses that should be given in order to have
L(T ) < L∗. In Figure 4.10 we can see the graphic representation of the tumor evolution with
N = 1, 2, . . . to the minimum N verifying the previous condition.
Figure 4.10: Tumor size evolution with N doses of 25 mg/m2 given every 21 days.
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It is noted that the lowest value of N so that L(T ) < L∗ is 4. That is, 4 doses of 25 mg/m
2 should
be given every 21 days. In total, 100 mg/m2 are given and L(T ) = 0.4566.
If the doses are of 20 mg/m2, then the lowest feasible N is 5 and L(T ) = 0.4168, again the
cumulative dose is 100 mg/m2. If the dose is 15 mg/m2, N = 6, L(T ) = 0.4351 and the total dose
given is 90 mg/m2. Figure 4.11 shows the graphic representation of the volume of the tumor for
these two cases:
Figure 4.11: Tumor size evolution with N doses of 20 mg/m2 given every 21 days (left) and doses
of 15 mg/m2 (right).
In Table 4.7 we can see a summary of the results obtained in this case for each usual treatment.
Treatment L(T) Total dose
25 mg/m2 every 21 days 0.4566 100 mg/m2
20 mg/m2 every 21 days 0.4170 100 mg/m2
15 mg/m2 every 21 days 0.4354 90 mg/m2
Table 4.7: Results obtained for problem (P̂2) with Cabazitaxel.
In this case, the third treatment seems to be the best in relation to the problem we want to solve,
as it minimizes the total dose. On the other hand, we can observe that in those treatments where
the same accumulated dose is given (rows 2 and 3 of Table 4.7), the best results are obtained when
lower doses are given but a greater number of them. Finally, let us note that it is more effective
to give many smaller doses, but a greater number of them, than few larger doses. This is observed
in rows 1 and 3 of Table 4.7, where results are better when 6 doses of 15 mg/m2 are given than




To conclude this study, let’s go back to the two optimization problems we have analyzed: (P1) and
(P2), which we introduced in Chapter 2. We have studied them for the two most common models
in pharmacodynamics: Emax and Skipper. Also. we have observed that the optimal treatment
depends on the type of drug administered, mainly if it has a long or short half-life.
With the Skipper model, for both problems and both types of drugs, the optimal treatment
consists of doses administrated following the scheme: (dmax, . . . , dmax, d
∗, dmin, . . . , dmin), with
dmin ≤ d∗ ≤ dmax, as we explained in Theorems 3.1.2 and 3.2.2. However, we have noted that for
the problem (P1), if the drug is short-lived, only the total sum of the doses administered influences
the value of L(T ) (this doesn’t happen if it’s a long-life drug). In Table 5.1 we show a summary
of the most recommendable treatments for each case and each type of drug, which in this case is
always the same.
Problems (P1) and (P2), Skipper model
Type of drug Optimal treatment
Short-life (dmax, . . . , dmax, d
∗, dmin, . . . , dmin)
Long-life (dmax, . . . , dmax, d
∗, dmin, . . . , dmin)
Table 5.1: Summary of the results obtained for problems (P1) and (P2) with the Skipper model.
For the usual treatments of the drugs under study, the same dose is always given throughout the
cycle. For this reason, we have contrasted the results of Table 5.1 using the Examples 3.1.1 and
3.1.2 for the problem (P1) and the Example 3.2.1 for the problem (P2).
On the other hand, for the Emax model, to study the problem (P1), both the type of drug and
the value of the constant k̂2 has influence. In Table 5.2 we can see the optimal treatment for the
problem (P1) depending on the type of drug and the value of k̂2.
Problem (P1), Emax model
Type of drug k̂2 Optimal treatment
Short-life
k̂2 ∈ (0, 1) Depends on the value of dmin and dmax
k̂2 ≥ 1 Metronomic chemotherapy
Long-life k̂2 > 0 (dmax, . . . , dmax, d
∗, dmin, . . . , dmin)
Table 5.2: Summary of the results obtained for problem (P1) and Emax model.
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In the case of drugs with short-life and k̂2 ∈ (0, 1), the optimal treatment depends on the value of
dmin and dmax, and can be MTD therapy, metronomic chemotherapy, or another type of treatment
as explained in Subsection 4.1.1, but all of them verifying that all the doses administered are
equal (still, remember that in most cases k̂2 > 1). As in the Skipper case, for short half-life
drugs, we obtain again that the optimal treatment is: (dmax, . . . , dmax, d
∗, dmin, . . . , dmin), with
dmin ≤ d∗ ≤ dmax.
Regarding the problem (P2) for the Emax case, if the drug has a short half-life, we have obtained
that the most recommendable treatment is the metronomic one, with all doses being equal.
However, the resolution of this problem for long half-life drugs is more complex. Although we
have not explicitly solved it for that case, as we have formulated (P̃N2E), we can compare several
treatments that are reasonable (exposed by specialists), and decide which one will give better
results in theory. The fact that we have formulated the problem allows us to reduce the number
of treatments to be studied, since those that are not feasible can quickly be discarded. This can
greatly facilitate clinical practice by reducing it to those treatments that have been proven to give
the best results.
To support these theoretical results, we have performed numerical simulations for both models and
both problems for a short half-life drug, Temozolomide, and for a long half-life one, Cabazitaxel.
With the numerical experiments carried out for these drugs we have also found that, in many
cases, the treatment which gives the best results is metronomic chemotherapy.
There are certain biological processes that make metronomic chemotherapy work better than MTD
therapy, such as angiogenesis. However, we have not taken into account this type of process (as
we have always considered θ fixed, while if we consider angiogenesis this parameter should grow
with the tumor size). We want to emphasize that even so, following mathematical reasoning,
there are many cases in which we obtain that metronomic chemotherapy gives better results than
MTD therapy. Differentiating the advantages of these two therapies is a frequent discussion in the
oncological field (see, for instance [5]), and with this study we want to provide a mathematical view
of the problem, which in most cases leads us to choose as the best option metronomic chemotherapy.
As for future lines of research, it may be interesting to study these problems by leaving the times
at which doses are administered as variables. We have tried to carry out this study but it is really
complex because clinical knowledge is needed to know how much time should pass between one
dose and another, both for reasons of effectiveness and toxicity of the treatment. In addition, it is
also pending to study the characteristics of the problem (P2E) for the case λ ≈ 0.
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Weierstrass extreme value theorem




subject to x ∈ K
.
Theorem A.0.1. ([2]). If f is a continuous function and K is a compact set, then exists at least
a global solution for (P ) .
Proof. Be µ = inf{f(x) : x ∈ K}. We know that there is a minimizing sequence (x(k))k∈N such as{
(x(k))k∈N ⊂ K
f(x(k)) −→ µ, when k → +∞
. (A.1)
As K is compact, it’s bounded in RN , so there is a convergent subsequence (x(k′))k′∈N ⊂ (x(k))k∈N
such as x(k
′) −→ x ∈ K (K is closed) when k′ → +∞. As f is continuous, f(x(k′)) −→ f(x) when
k′ → +∞. Also, by (A.1), f(x(k′)) −→ µ, when k′ → +∞. Therefore, because of the uniqueness
of the limit in R, f(x) = µ.




Inequality of arithmetic and
geometric means











Proposition B.0.1. ([21]). The arithmetic mean of a set of positive numbers (di ∈ R+, i ∈











Moreover, the equality is only obtained when di = dj, ∀i, j ∈ {1, . . . , N}.






the equality in the equation (B.1). Now, let’s prove (B.1) by induction:





d1d2 =⇒ d21 + d22 − 2d1d2 = (d1 − d2)2 ≥ 0.
Here we can note that we get the equality if and only if d1 = d2.
• Now let’s suppose that (B.1) holds for k ∈ N (and the equality is only obtained for d1 =
. . . = dk), and let’s prove it for 2k.
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d1 . . . d2k. (B.2)
Note that the equality is only given if d1 = . . . = dk and dk+1 . . . = d2k (by the hypothesis














IV APPENDIX B. INEQUALITY OF ARITHMETIC AND GEOMETRIC MEANS
and by the case N = 2, the equality is only fulfilled if d1 = dk+1, and then in (B.2) we get
the equality if and only if d1 = . . . = d2k.
• We assume (B.1) for k (inductive hypothesis), and let’s prove it for k − 1:
We’re going to apply the inductive hypothesis to d1, d2, . . . , dk−1 and its arithmetic mean:
d1 + . . .+ dk−1
k − 1
=






d1 . . . dk−1
(




=⇒ d1 + . . .+ dk−1
k − 1















≥ (d1 . . . dk−1)
1




d1 . . . dk−1.
By the inductive hypothesis, in the first inequality we only get the equality if d1 = . . . =
dk−1 =
d1 + . . .+ dk−1
k − 1
, so the last equality is only fulfilled if d1 = . . . = dk−1.
Appendix C
Lambert W function
Lambert W function (omega function or product logarithm) is defined as the inverse of the
function f(w) = wew, with w ∈ R (see [23]). This function is usually represented by W . In Figure
C.1 we show the graphic representation of the function f(w) = wew for w ∈ [−5, 2]:
Figure C.1: f(w) = wew.
Note that this function is not injective. If the argument is real, Lambert W function is only defined
for z ≥ −1/e, and also for z ∈ (−1/e, 0), because there are two branches. The principal branch is
known as W0, for which we know some values: W0(−1/e) = −1, W0(0) = 0, W0(e) = 1...
Each function Wk(z) is injective, and all of then have disjointed ranges. For example, in Figure
C.2 we see the graphic of the branch W0(z) for z ∈ [−1/e, 10], and in Figure C.3, that of the
branch W−1(z) for z ∈ [−1/e, 1].
Figure C.2: W0(z) Figure C.3: W−1(z)
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